Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Pharmacodynamics of Telavancin Studied in an In Vitro Pharmacokinetic Model of Infection

Alasdair P. MacGowan, Alan R. Noel, Sharon Tomaselli, Heather C. Elliott, Karen E. Bowker
Alasdair P. MacGowan
Bristol Centre for Antimicrobial Research and Evaluation (BCARE), University of Bristol and North Bristol NHS Trust, Department of Medical Microbiology, Lime Walk Building, Southmead Hospital, Westbury-on-Trym, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alasdair.macgowan@nbt.nhs.uk
Alan R. Noel
Bristol Centre for Antimicrobial Research and Evaluation (BCARE), University of Bristol and North Bristol NHS Trust, Department of Medical Microbiology, Lime Walk Building, Southmead Hospital, Westbury-on-Trym, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Tomaselli
Bristol Centre for Antimicrobial Research and Evaluation (BCARE), University of Bristol and North Bristol NHS Trust, Department of Medical Microbiology, Lime Walk Building, Southmead Hospital, Westbury-on-Trym, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather C. Elliott
Bristol Centre for Antimicrobial Research and Evaluation (BCARE), University of Bristol and North Bristol NHS Trust, Department of Medical Microbiology, Lime Walk Building, Southmead Hospital, Westbury-on-Trym, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen E. Bowker
Bristol Centre for Antimicrobial Research and Evaluation (BCARE), University of Bristol and North Bristol NHS Trust, Department of Medical Microbiology, Lime Walk Building, Southmead Hospital, Westbury-on-Trym, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00933-10
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Antibacterial effect of simulated human free-drug serum concentration-time profiles of telavancin, vancomycin, and teicoplanin against MSSA strain 38002 (a), MRSA strain 36895 (b), and VISA strain 19898 (c). The error bars indicate standard deviations.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Antibacterial effect of simulated human free-drug serum concentration-time profiles of telavancin, vancomycin, and teicoplanin against E. faecalis strain 37976 (a), E. faecium strain 37780 (b), and vancomycin-resistant E. faecium strain 31040 (c). The error bars indicate standard deviations.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Telavancin fAUC/MIC relationship AUBKC24 for vancomycin-susceptible S. aureus (a) and Enterococcus spp. (b).

Tables

  • Figures
  • TABLE 1.

    Telavancin, vancomycin, and teicoplanin MICs for S. aureus and the Enterococcus spp. used

    Strain typeStrain no.MIC (mg/liter)
    TelavancinVancomycinTeicoplanin
    MRSA227060.251.50.12
    MRSA330240.190.190.25
    MRSA368950.192.00.19
    MSSA380020.381.50.25
    MRSA386010.191.00.19
    VISA198980.75816
    VISA247641.0
    VISA259491.0
    VISA260890.75
    E. faecalis379760.250.750.12
    E. faecium377800.120.250.12
    E. faecium (VR)310401.51281.5
  • TABLE 2.

    Pharmacokinetic parameters for telavancin, vancomycin, and teicoplanin

    ParameteraValue
    TelavancinVancomycinTeicoplanin
    Cmax (mg/liter)11.1 ± 2.513.9 ± 0.23.6 ± 0.9
    AUC0-24 (mg/liter·h)95.7 ± 3.3193.4 ± 16.243.6 ± 11.2
    t1/2 (h)7.4 ± 0.35.0 ± 0.414.0 ± 6.0
    C at 12 h (mg/liter)2.1 ± 0.54.4 ± 1.01.6 ± 0.6
    C at 24 h (mg/liter)<1<1
    • ↵a C, concentration.

  • TABLE 3.

    Comparative antibacterial effects of free-drug serum concentrations of simulations of telavancin, teicoplanin, and vancomycin against pooled data from 4 MRSA strains

    ABE measureValue
    TelavancinTeicoplaninVancomycin
    No. of simulations181217
    Log change in viable count (log CFU/ml) at (h):
        6−3.5 ± 0.6a−2.0 ± 0.4−2.5 ± 0.7
        12−3.5 ± 0.5a−2.7 ± 0.2−3.0 ± 0.7
        24−3.0 ± 0.8−2.8 ± 0.5−2.8 ± 0.8
        36−3.0 ± 0.7−2.7 ± 0.8−2.7 ± 0.9
        48−2.8 ± 0.8−2.1 ± 1.4−2.8 ± 1.0
    Maximum reduction in viable count (log CFU/ml)−4.0 ± 0.5a−3.2 ± 0.5−3.3 ± 0.6
    AUBKC24 (log CFU/ml·h)21.7 ± 7.7a42.0 ± 5.336.9 ± 13.7
    AUBKC48 (log CFU/ml·h)43.8 ± 20.0a76.3 ± 21.165.9 ± 29.4
    • ↵a Telavancin was superior to vancomycin and teicoplanin (P < 0.05).

  • TABLE 4.

    Relationship between telavancin free-drug AUC/MIC ratio and antibacterial effect at 24 h for vancomycin-susceptible S. aureus, vancomycin-intermediate S. aureus, and Enterococcus spp.

    StrainTelavancin MIC (μg/ml)fAUC/MIC ratio
    Static effect−1-log-unit reduction in viable count−2-log-unit reduction in viable count
    MRSA
        330240.1995.098.4105.5
        368950.1967.780.495.5
        386010.1937.843.3
        277060.2511.823.549.6
        380020.383.14.415.8
        Mean ± SD43.1 ± 38.450.0 ± 39.055.1 ± 37.2
    VISA
        198980.752.13.14.7
        260890.754.86.17.4
        247641.02.33.65.9
        259491.03.74.76.0
        Mean ± SD3.2 ± 1.34.3 ± 1.36.0 ± 1.1
    E. faecium 377800.1217.060.2
    E. faecalis 379760.255.66.3
    VR E. faecium 310401.522.953.7170
        Mean ± SD15.1 ± 8.840.1 ± 29.4
  • TABLE 5.

    Relationship between telavancin free-drug AUC/MIC ratio and risk of emergence of resistance in vancomycin-susceptible S. aureus and Enterococcus sp. strains as assessed by organism growth on 2× MIC recovery media

    fAUC/MIC ratioS. aureusEnterococcus spp.
    No. of expt% with growth on 2× MIC recovery media (n)Viable count (log CFU/ml) on 2× MIC recovery platesNo. of expt% with growth on 2× MIC recovery media (n)Viable count (log CFU/ml) on 2× MIC recovery plates
    <1030<2
    ≥1-38100 (8)5.6 ± 1.9729 (2)3.6
    >3-103100 (3)4.7 ± 0.6560 (3)3.1 ± 0.9
    >10-50850 (4)4.3 ± 1.1617 (1)4.4
    >50-175729 (2)4.230<2
    >175-400714 (1)2.140<2
    >40050<250<2
PreviousNext
Back to top
Download PDF
Citation Tools
Pharmacodynamics of Telavancin Studied in an In Vitro Pharmacokinetic Model of Infection
Alasdair P. MacGowan, Alan R. Noel, Sharon Tomaselli, Heather C. Elliott, Karen E. Bowker
Antimicrobial Agents and Chemotherapy Jan 2011, 55 (2) 867-873; DOI: 10.1128/AAC.00933-10

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacodynamics of Telavancin Studied in an In Vitro Pharmacokinetic Model of Infection
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pharmacodynamics of Telavancin Studied in an In Vitro Pharmacokinetic Model of Infection
Alasdair P. MacGowan, Alan R. Noel, Sharon Tomaselli, Heather C. Elliott, Karen E. Bowker
Antimicrobial Agents and Chemotherapy Jan 2011, 55 (2) 867-873; DOI: 10.1128/AAC.00933-10
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596